Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events

Renal toxicities have been increasingly recognized as complications of the immune checkpoint inhibitors (ICIs). Recent studies have outlined the incidence and potential risk factors for nephrotoxicity. For clinicians, the key question is how to manage patients who develop these adverse renal effects...

Full description

Saved in:
Bibliographic Details
Published in:Kidney international reports 2020-08, Vol.5 (8), p.1139-1148
Main Authors: Herrmann, Sandra M., Perazella, Mark A.
Format: Article
Language:English
Subjects:
acute intertitial nephritis
CTLA-4
immune checkpoint inhibitors
immunotherapy
PD-L1
PD1
renal immune-related adverse effect
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Renal toxicities have been increasingly recognized as complications of the immune checkpoint inhibitors (ICIs). Recent studies have outlined the incidence and potential risk factors for nephrotoxicity. For clinicians, the key question is how to manage patients who develop these adverse renal effects. This is of paramount importance to providers as ICI use for cancer therapy becomes more widespread and nephrotoxicity increasingly develops. As clinicians encounter ICI-associated nephrotoxicity, an appropriate approach to management is required to facilitate the best outcomes in patients with cancer. Importantly, ICI rechallenge in patients who developed ICI-related acute kidney injury (AKI) is unclear and represents a conundrum for providers. Clinicians struggle with the “if, when, and how to” questions related to ICI rechallenge in this subset of patients. In addition, ICI use in the transplant population raises concerns for promoting acute rejection when treating cancer in these patients. We herein review current information on these various topics.
ISSN:2468-0249
2468-0249
DOI:10.1016/j.ekir.2020.04.018